JOP20200082B1 - علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول - Google Patents
علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديولInfo
- Publication number
- JOP20200082B1 JOP20200082B1 JOJO/P/2020/0082A JOP20200082A JOP20200082B1 JO P20200082 B1 JOP20200082 B1 JO P20200082B1 JO P20200082 A JOP20200082 A JO P20200082A JO P20200082 B1 JOP20200082 B1 JO P20200082B1
- Authority
- JO
- Jordan
- Prior art keywords
- fragile
- syndrome
- cannabidiol
- treatment
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
تتعلق التقنية الحالية بطريقة لعلاج واحد أو أكثر من الأعراض السلوكية لمتلازمة الكروموسوم إكس الهش في خاضع عن طريق إعطاء كمية فعالة من الكانابيديول (CBD) للخاضع عبر الأمة حيث يتم علاج واحد أو أكثر من الأعراض السلوكية لمتلازمة الكروموسوم إكس الهش في الخاضع.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762564834P | 2017-09-28 | 2017-09-28 | |
| US201862632532P | 2018-02-20 | 2018-02-20 | |
| PCT/IB2018/057519 WO2019064234A1 (en) | 2017-09-28 | 2018-09-27 | TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JOP20200082A1 JOP20200082A1 (ar) | 2020-04-30 |
| JOP20200082B1 true JOP20200082B1 (ar) | 2024-12-22 |
Family
ID=63878731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2020/0082A JOP20200082B1 (ar) | 2017-09-28 | 2020-04-30 | علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول |
Country Status (22)
| Country | Link |
|---|---|
| US (13) | US10213390B1 (ar) |
| EP (3) | EP3687513B1 (ar) |
| JP (5) | JP7210564B2 (ar) |
| KR (2) | KR102786277B1 (ar) |
| AU (2) | AU2018343256B2 (ar) |
| BR (1) | BR112020005918A2 (ar) |
| CA (2) | CA3077330A1 (ar) |
| CY (1) | CY1125071T1 (ar) |
| DK (1) | DK3687513T3 (ar) |
| ES (2) | ES2992838T3 (ar) |
| HR (1) | HRP20220277T1 (ar) |
| HU (1) | HUE058102T2 (ar) |
| IL (1) | IL273495A (ar) |
| JO (1) | JOP20200082B1 (ar) |
| LT (1) | LT3687513T (ar) |
| MX (2) | MX2020003606A (ar) |
| PL (1) | PL3687513T3 (ar) |
| PT (1) | PT3687513T (ar) |
| RS (1) | RS62969B1 (ar) |
| SI (1) | SI3687513T1 (ar) |
| SM (1) | SMT202200093T1 (ar) |
| WO (1) | WO2019064234A1 (ar) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12582664B2 (en) | 2017-09-28 | 2026-03-24 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| MX2020003606A (es) * | 2017-09-28 | 2020-10-28 | Zynerba Pharmaceuticals Inc | Tratamiento del sindrome del cromosoma x fragil con canabidiol. |
| MX2021007076A (es) | 2018-12-14 | 2021-08-11 | Zynerba Pharmaceuticals Inc | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. |
| GB201912760D0 (en) * | 2019-09-05 | 2019-10-23 | Healx Ltd | Treatment |
| EP4706647A3 (en) * | 2019-09-17 | 2026-05-20 | Harmony Biosciences Man Inc | SYNGAP1 ENCEPHALOPATHY TREATMENT |
| EP4037663A1 (en) | 2019-10-03 | 2022-08-10 | Starton Therapeutics, Inc. | Transdermal delivery of dronabinol |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| US12186280B2 (en) | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| CN114555068A (zh) | 2019-10-14 | 2022-05-27 | 长矛治疗股份有限公司1219014 B.C.有限公司 | 大麻二酚的透皮给药 |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| GB2589306A (en) * | 2019-10-25 | 2021-06-02 | Gw Res Ltd | Use of cannabidiol preparations in the treatment of fragile X syndrome |
| WO2021158059A1 (ko) | 2020-02-07 | 2021-08-12 | 건국대학교 글로컬산학협력단 | 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물 |
| KR20230016003A (ko) * | 2020-05-26 | 2023-01-31 | 지네르바 파마슈티컬스, 인코포레이티드 | 칸나비디올을 사용하는 자폐 스펙트럼 장애의 치료 |
| IL299399A (en) * | 2020-06-29 | 2023-02-01 | Zynerba Pharmaceuticals Inc | Treatment of fragile X syndrome with cannabidiol |
| MX2023006551A (es) * | 2020-12-03 | 2023-08-17 | Zynerba Pharmaceuticals Inc | Tratamiento de las convulsiones refractarias. |
| CN116782891A (zh) * | 2020-12-03 | 2023-09-19 | Zyne制药公司 | 大麻二酚对难治性癫痫发作的治疗 |
| AU2022373753A1 (en) * | 2021-10-22 | 2024-05-09 | Harmony Biosciences Management, Inc. | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| FI111733B (fi) | 2002-02-20 | 2003-09-15 | Pedipharm Oy | Uudet metyloidut syklodekstriinikompleksit |
| TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
| US20080139472A1 (en) * | 2006-10-06 | 2008-06-12 | The Regents Of The University Of California | Upregulating bdnf levels to mitigate mental retardation |
| ES2534900T3 (es) | 2007-07-30 | 2015-04-30 | Zynerba Pharmaceuticals, Inc. | Profármacos de cannabidiol, composiciones que comprenden los profármacos de cannabidiol y métodos de uso de los mismos |
| CA2760460C (en) | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
| CA2772634C (en) | 2009-08-31 | 2017-11-21 | Alltranz Inc. | Use of cannabidiol prodrugs in topical and transdermal administration with microneedles |
| EP2943463B1 (en) | 2013-01-08 | 2021-07-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Fluorinated cbd compounds, compositions and uses thereof |
| AU2014340709B2 (en) | 2013-10-29 | 2019-07-04 | Echo Pharmaceuticals B.V. | Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders |
| US20160022627A2 (en) | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
| US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| CA2950424C (en) | 2014-05-29 | 2023-03-14 | Insys Pharma, Inc. | Stable cannabinoid formulations |
| US12544389B2 (en) | 2014-05-29 | 2026-02-10 | Fresh Cut Development, Llc | Stable cannabinoid formulations |
| US20160271252A1 (en) | 2014-05-29 | 2016-09-22 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| EP3160451B1 (en) | 2014-06-27 | 2021-04-07 | Farm To Farma, Inc. | Buccal and sublingual cannabinoid formulations and method of making the same |
| WO2016004121A1 (en) | 2014-07-01 | 2016-01-07 | MJAR Holdings, LLC | High cannabidiol cannabis strains |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| CA3135893C (en) | 2014-10-21 | 2023-11-14 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
| US9375417B2 (en) | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
| WO2016109624A1 (en) | 2014-12-30 | 2016-07-07 | University Of Houston System | Pharmaceutical compositions |
| US20160338974A1 (en) | 2015-03-02 | 2016-11-24 | Afgin Pharma, Llc | Topical regional neuro affective therapy with cannabinoid combination products |
| HK1244715A1 (zh) * | 2015-03-02 | 2018-08-17 | 阿福金制药有限责任公司 | 用大麻素的局部区域神经影响性疗法 |
| WO2017068349A1 (en) | 2015-10-23 | 2017-04-27 | E-Therapeutics Plc | Cannabinoid for use in immunotherapy |
| WO2017151980A1 (en) | 2016-03-03 | 2017-09-08 | Segreti Louis M | Cannabis-based bioactive formulations and methods for use thereof |
| EP3423047A4 (en) | 2016-03-04 | 2020-01-01 | Sharon Anavi-Goffer | COMPOSITIONS OF CB2 RECEPTOR SELECTIVE AGONISTS FOR THE TREATMENT OF MENTAL DISEASES |
| PT3429580T (pt) | 2016-03-16 | 2025-08-12 | Buzzelet Development And Technologies Ltd | Composição de canabinoides enriquecida em terpenos |
| GB2549277B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
| GB2549278B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| IL262419B2 (en) | 2016-04-19 | 2024-08-01 | Canna B Cure Ltd | Cannabis-enriched enzymatically treated therapeutic composition |
| EP3478270A4 (en) | 2016-06-02 | 2019-11-27 | Acerus Labs, Inc. | HALF-RESISTANT AND VISCOUS LIQUID, NADAL FORMULATIONS OF CANNABINOIDS |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| IL246790A0 (en) | 2016-07-14 | 2016-09-29 | Friedman Doron | Self-dissolving compounds of cannabinoids |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| CN107126411A (zh) * | 2017-03-22 | 2017-09-05 | 哈尔滨惠美佳生物科技有限公司 | 具有缓解神经性头痛作用的大麻二酚凝胶及其制备方法 |
| WO2019034985A1 (en) | 2017-08-14 | 2019-02-21 | Zynerba Pharmaceuticals, Inc. | METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL |
| SG11202002169TA (en) | 2017-09-15 | 2020-04-29 | Zelda Therapeutics Operations Pty Ltd | Composition and method for treating autism |
| US12582664B2 (en) | 2017-09-28 | 2026-03-24 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| MX2020003606A (es) | 2017-09-28 | 2020-10-28 | Zynerba Pharmaceuticals Inc | Tratamiento del sindrome del cromosoma x fragil con canabidiol. |
| EP3703672A4 (en) | 2017-10-30 | 2021-12-01 | Endocanna Health, Inc. | CANNABINOID FORMULATIONS |
| JP2021525709A (ja) | 2018-05-24 | 2021-09-27 | ティーオー ファーマスーティカルズ リミテッド ライアビリティー カンパニーＴＯ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＬＬＣ | 自閉症スペクトラム障害の治療のためのカンナビスベースの組成物 |
| US20230000793A1 (en) | 2018-12-14 | 2023-01-05 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
| US20230000792A1 (en) | 2018-12-14 | 2023-01-05 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
| MX2021007076A (es) | 2018-12-14 | 2021-08-11 | Zynerba Pharmaceuticals Inc | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. |
| KR20230016003A (ko) | 2020-05-26 | 2023-01-31 | 지네르바 파마슈티컬스, 인코포레이티드 | 칸나비디올을 사용하는 자폐 스펙트럼 장애의 치료 |
| IL299399A (en) | 2020-06-29 | 2023-02-01 | Zynerba Pharmaceuticals Inc | Treatment of fragile X syndrome with cannabidiol |
| GB2597322A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| AU2022373753A1 (en) | 2021-10-22 | 2024-05-09 | Harmony Biosciences Management, Inc. | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance |
-
2018
- 2018-09-27 MX MX2020003606A patent/MX2020003606A/es unknown
- 2018-09-27 EP EP18788905.0A patent/EP3687513B1/en active Active
- 2018-09-27 AU AU2018343256A patent/AU2018343256B2/en active Active
- 2018-09-27 HR HRP20220277TT patent/HRP20220277T1/hr unknown
- 2018-09-27 SM SM20220093T patent/SMT202200093T1/it unknown
- 2018-09-27 ES ES21206188T patent/ES2992838T3/es active Active
- 2018-09-27 WO PCT/IB2018/057519 patent/WO2019064234A1/en not_active Ceased
- 2018-09-27 US US16/144,632 patent/US10213390B1/en active Active
- 2018-09-27 PT PT187889050T patent/PT3687513T/pt unknown
- 2018-09-27 EP EP24174294.9A patent/EP4414030A3/en active Pending
- 2018-09-27 RS RS20220123A patent/RS62969B1/sr unknown
- 2018-09-27 CA CA3077330A patent/CA3077330A1/en active Pending
- 2018-09-27 KR KR1020207012201A patent/KR102786277B1/ko active Active
- 2018-09-27 EP EP21206188.1A patent/EP3967301B1/en active Active
- 2018-09-27 JP JP2020517930A patent/JP7210564B2/ja active Active
- 2018-09-27 CA CA3300266A patent/CA3300266A1/en active Pending
- 2018-09-27 BR BR112020005918-8A patent/BR112020005918A2/pt unknown
- 2018-09-27 HU HUE18788905A patent/HUE058102T2/hu unknown
- 2018-09-27 LT LTEPPCT/IB2018/057519T patent/LT3687513T/lt unknown
- 2018-09-27 ES ES18788905T patent/ES2907325T3/es active Active
- 2018-09-27 SI SI201830564T patent/SI3687513T1/sl unknown
- 2018-09-27 PL PL18788905T patent/PL3687513T3/pl unknown
- 2018-09-27 DK DK18788905.0T patent/DK3687513T3/da active
- 2018-09-27 KR KR1020227010520A patent/KR20220045070A/ko not_active Ceased
- 2018-12-14 US US16/220,249 patent/US10314792B2/en active Active
-
2019
- 2019-01-16 US US16/249,732 patent/US10471022B2/en active Active
- 2019-05-14 US US16/411,248 patent/US10568848B2/en active Active
- 2019-10-07 US US16/594,317 patent/US10758497B2/en active Active
-
2020
- 2020-01-08 US US16/737,326 patent/US20200214995A1/en not_active Abandoned
- 2020-03-22 IL IL273495A patent/IL273495A/en unknown
- 2020-04-30 JO JOJO/P/2020/0082A patent/JOP20200082B1/ar active
- 2020-07-13 MX MX2022012424A patent/MX2022012424A/es unknown
- 2020-08-06 US US16/986,622 patent/US11458110B2/en active Active
-
2021
- 2021-09-02 US US17/465,141 patent/US20220096396A1/en not_active Abandoned
-
2022
- 2022-02-03 JP JP2022015432A patent/JP2022064988A/ja active Pending
- 2022-02-22 CY CY20221100148T patent/CY1125071T1/el unknown
- 2022-08-24 US US17/895,008 patent/US11779549B2/en active Active
-
2023
- 2023-01-10 JP JP2023001500A patent/JP2023040166A/ja active Pending
- 2023-03-21 US US18/124,460 patent/US12213951B2/en active Active
- 2023-08-30 US US18/458,727 patent/US12226373B2/en active Active
-
2024
- 2024-09-25 AU AU2024220039A patent/AU2024220039A1/en active Pending
-
2025
- 2025-01-02 US US19/008,407 patent/US20250134832A1/en active Pending
- 2025-01-06 US US19/011,503 patent/US20250134833A1/en active Pending
- 2025-01-16 JP JP2025005981A patent/JP2025061375A/ja active Pending
- 2025-03-21 JP JP2025046396A patent/JP2025106310A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200082A1 (ar) | علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول | |
| JOP20210140A1 (ar) | معالجة متلازمة الحذف 22q11.2 بكانابيديول | |
| EA201890411A1 (ru) | Терапевтически активные соединения и способы их применения | |
| MX2022003193A (es) | Tratamiento de encefalopatia asociada al gen syngap1. | |
| CA2909335C (en) | Fenfluramine for use in the treatment of dravet syndrome | |
| EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
| MX383691B (es) | Método de tratamiento de cáncer asociado con una mutación de ras. | |
| EA201591327A1 (ru) | Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений | |
| BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| BR112018004680A2 (pt) | método de tratamento de distúrbios de desenvolvimento | |
| EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| MX2019003703A (es) | Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23. | |
| MX372990B (es) | Composiciones para el tratamiento del ojo seco. | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| EA201690997A1 (ru) | Композиция для применения в лечении стойкого кашля | |
| JOP20230125A1 (ar) | كانابيديول لعلاج النوبات المستعصية على العلاج | |
| EA202091446A1 (ru) | Способы лечения хронических воспалительных заболеваний | |
| EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
| JOP20220310A1 (ar) | علاج اضطراب طيف التوحد بكانابيديول | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| MX2019012659A (es) | Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido. | |
| MX382608B (es) | Tratamiento del prurito urémico. | |
| EA201690445A1 (ru) | Лечение рака |